ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

DTaP-IPV-HB-PRP~T combined vaccine

Its studies are mostly in Diphtheria, led by Sanofi.

Furthest: phase 3, since Nov 10, 20261 company-led study, 1 open or runningNext primary completion: Apr 27, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi11 open or runningphase 3since Nov 10, 2026Nov 10, 2026Apr 27, 2028phase 3 · NCT07941622

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 10, 2026First study: phase 3 study in Haemophilus Influenzae Type b ImmunisationFirst studyNCT07941622 · 720 planned

Ahead

  1. Apr 27, 2028Primary completion: phase 3 study in Haemophilus Influenzae Type b ImmunisationNCT07941622

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“DTaP-IPV-HB-PRP~T combined vaccine”name, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07941622Haemophilus Influenzae Type b Immunisation3Not yet recruitingApr 27, 2028720

How it is read

Names in the registry

  • “DTaP-IPV-HB-PRP~T combined vaccine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 18, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.